Skip to main content
    H

    Halozyme Therapeutics Inc (HALO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $121.51
    +4.69 (+4.01%)

    Market Cap: $13.26B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    72%(28/39)
    Avg Surprise
    +6.84%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$2.32
    Range$2.20 - $2.37
    5 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$2.19+6.0%
    60d ago$2.29+1.3%
    30d ago$2.29+1.3%
    7d ago$2.29+1.3%
    Current$2.32
    Revenue Consensus
    $490M
    Range$482M - $495M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$3.05
    Range$2.25 - $3.30
    5 analysts
    Revenue Consensus
    $635M
    Range$611M - $658M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.05---
    Sep 26EST
    		-$2.32---
    Jun 26
    Reported Aug 6
    		$2.17$1.73+25.43%Beat+40.9%
    Mar 26
    Reported May 11
    		$1.22$1.76-30.61%Miss+10.0%
    Dec 25
    Reported Feb 17
    		$-0.24N/A-110.91%Miss-119.0%
    Sep 25
    Reported Nov 3
    		$1.72$1.63+5.52%Beat+35.4%
    Jun 25
    Reported Aug 5
    		$1.54$1.27+21.26%Beat+69.2%
    Mar 25
    Reported May 6
    		$1.11$0.95+16.84%Beat+40.5%
    Dec 24
    Reported Feb 18
    		$1.26$1.16+8.73%Beat+53.7%
    Sep 24
    Reported Oct 31
    		$1.27$0.98+29.59%Beat+69.3%
    Jun 24
    Reported Aug 6
    		$0.91$0.76+19.74%Beat+23.0%
    Mar 24
    Reported May 7
    		$0.79$0.70+12.86%Beat+68.1%
    Dec 23
    Reported Feb 20
    		$0.82$0.83-1.20%Miss+70.8%
    Sep 23
    Reported Nov 6
    		$0.75$0.71+5.63%Beat+1.4%
    Jun 23
    Reported Aug 8
    		$0.74$0.64+15.63%Beat+39.6%
    Mar 23
    Reported May 9
    		$0.47$0.48-2.08%Miss+0.0%
    Dec 22
    Reported Feb 21
    		$0.48$0.47+2.13%Beat+14.3%
    Sep 22
    Reported Nov 8
    		$0.74$0.51+45.10%Beat+34.5%
    Jun 22
    Reported Aug 9
    		$0.53$0.50+6.00%Beat-19.7%
    Mar 22
    Reported May 10
    		$0.47$0.49-4.08%Miss+27.0%
    Dec 21
    Reported Feb 22
    		$0.42$0.41+2.44%Beat-16.0%
    Sep 21
    Reported Nov 2
    		$0.55$0.48+14.58%Beat+120.0%
    Jun 21
    Reported Aug 9
    		$0.66$0.44+50.00%Beat+247.4%
    Mar 21
    Reported May 10
    		$0.37$0.31+19.35%Beat+1025.0%
    Dec 20
    Reported Feb 23
    		$0.50$0.53-5.66%Miss+308.3%
    Sep 20
    Reported Nov 2
    		$0.25$0.21+19.05%Beat+247.1%
    Jun 20
    Reported Aug 10
    		$0.19$0.25-24.00%Miss+290.0%
    Mar 20
    Reported May 11
    		$-0.04$-0.04+0.00%Beat-500.0%
    Dec 19
    Reported Feb 24
    		$-0.24$-0.14-71.43%Miss-2300.0%
    Sep 19
    Reported Nov 12
    		$-0.17$-0.13-30.77%Miss+10.5%
    Jun 19
    Reported Aug 6
    		$-0.10$-0.15+33.33%Beat+37.5%
    Mar 19
    Reported May 7
    		$0.01N/A-80.00%Miss+105.3%
    Dec 18
    Reported Feb 21
    		$-0.01N/A+66.67%Beat-101.2%
    Sep 18
    Reported Nov 6
    		$-0.19$-0.23+17.39%Beat-1050.0%
    Jun 18
    Reported Aug 7
    		$-0.16$-0.22+27.27%Beat+30.4%
    Mar 18
    Reported May 10
    		$-0.19$-0.22+13.64%Beat+26.9%
    Dec 17
    Reported Feb 20
    		$0.85$0.77+10.39%Beat+504.8%
    Sep 17
    Reported Nov 7
    		$0.02N/A+118.18%Beat-
    Jun 17
    Reported Aug 8
    		$-0.23$-0.24+4.17%Beat-
    Mar 17
    Reported May 9
    		$-0.26$-0.24-8.33%Miss-
    Dec 16
    Reported Feb 28
    		$-0.21$-0.28+25.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio24.94EV/EBITDA22.20x
    Price/FCF17.67xFCF Yield5.66%
    Profitability
    Profit Margin24.90%Operating Margin59.80%
    ROE173.70%ROIC18.86%
    Financial Health
    Debt/Equity14.95xInterest Coverage23.63x
    Current Ratio2.71xQuick Ratio2.31x
    Trading Statistics
    Beta0.88Avg Volume2.82M
    52-Week High$119.2152-Week Low$61.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$111.80
    SMA 20$112.02
    SMA 50$108.19
    SMA 200$80.34
    EMA 10$113.27
    EMA 20$111.60
    EMA 50$105.55
    EMA 200$85.58

    MACD

    Line: 2.23Signal: 1.75Hist: 0.48

    ADX

    ADX: 23.1+DI: 34.4-DI: 14.5

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down16.0
    PSAR$106.90

    Bollinger Bands

    Upper Band$118.60
    Lower Band$105.43
    %B Position1175%(Upper)
    Band Width1.22

    RSI (14-Day)

    Neutral
    70.0

    Momentum Oscillators

    Stoch %K69.1
    Stoch %D52.8
    Williams %R-5.2
    ROC (10d)13.6%
    Momentum14.57
    CCI (20d)266.4
    MFI (14d)49.4

    Volatility Measures

    ATR (14d)$3.72(3.1%)
    StdDev (20d)3.29
    Hist Vol38.6%(Moderate)

    Volume Flow

    VWAP$120.41
    OBV39.3M
    AD Line19.5M
    CMF (20d)0.087

    Volume Metrics

    Avg Vol (20d)2.9M
    Vol Ratio0.8x
    VWMA (20d)$112.39

    Pivot Points

    R3$130.67
    R2$124.94
    R1$120.88
    Pivot Point$115.15
    S1$111.09
    S2$105.36
    S3$101.30

    Advanced Oscillators

    TSI17.77
    Ultimate Osc54.8
    KST32.87

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$481.00M$376.71M$451.77M$354.26M$325.72M$264.86M$298.01M$290.08M$231.35M$195.88M$230.04M$216.03M
    Cost of Revenue$79.17M$79.24M$78.77M$55.24M$46.36M$48.40M$42.05M$49.43M$39.61M$28.33M$52.30M$54.82M
    Gross Profit$401.83M$297.47M$373.00M$299.02M$279.36M$216.46M$255.95M$240.66M$191.75M$167.55M$177.74M$161.21M
    Operating Expenses$114.17M$112.95M$465.89M$81.10M$76.92M$74.92M$80.45M$77.46M$74.51M$72.01M$76.71M$72.93M
    R&D$27.66M$25.56M$316.78M$17.25M$17.54M$14.80M$20.44M$18.46M$21.04M$19.11M$21.34M$17.32M
    SG&A$57.00M$57.88M$77.03M$46.09M$41.61M$42.36M$42.25M$41.24M$35.71M$35.13M$37.61M$35.27M
    Operating Income$287.65M$184.52M$-92,891,000$217.92M$202.44M$141.53M$175.50M$163.20M$117.23M$95.54M$101.03M$88.28M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$13.20M
    Interest Expense$5.59M$5.51M$10.39M$4.30M$4.39M$4.53M$4.54M$4.52M$4.52M$4.51M$5.22M$4.50M
    Income Before Tax$284.90M$180.33M$-100,849,000$218.96M$204.94M$143.83M$178.21M$165.15M$117.74M$96.03M$101.17M$101.76M
    Income Tax Expense$54.99M$30.28M$40.74M$43.73M$39.78M$25.73M$41.20M$28.14M$24.50M$19.20M$15.79M$19.92M
    Net Income$229.91M$150.05M$-141,591,000$175.22M$165.16M$118.09M$137.01M$137.01M$93.25M$76.82M$85.39M$81.84M
    EBITDA$326.11M$221.78M$-61,927,000$245.18M$230.55M$168.94M$202.62M$188.75M$141.40M$120.21M$126.43M$116.48M
    EBIT$290.49M$185.84M$-90,461,000$223.25M$209.33M$148.35M$182.75M$169.67M$122.27M$100.53M$106.39M$93.06M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Toll Booth on Biotech’s Highway: Why Halozyme’s Royalty Engine Could Make Patient Investors Rich

    Halozyme's ENHANZE platform is a toll booth on injectable biologics: partners develop drugs, HALO collects royalties on every dose sold across 10 commercialized products in 100+ global markets. Three major deals in 100 days: Elektrofi acquisition ($750M+ in Oct), Skye Bioscience (Jan 5)...

    Glenn Ford
    •
    1/14/26
    •
    188
    Biotech, value investing, Healthcare Stocks
    Also mentions:
    TAKJNJ

    News

    H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $130

    H.C. Wainwright has reiterated its Buy rating for Halozyme Therapeutics (HALO.US) and maintained a price target of $130. This continued endorsement suggests the firm's confidence in the company's future performance...

    Moomoo•10/15/26•Bullish

    Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today

    A $1000 investment in Halozyme Therapeutics (HALO) made ten years ago would now be worth $11,612.33, representing a 1,061.23% gain. This significantly outperforms the S&P 500's 261.89% and gold's 215.01% returns over...

    Yahoo Finance•10/15/26•Bullish

    Halozyme Therapeutics Inc. (HALO) Stock Price | Live Quotes & Charts | NASDAQ

    This page provides live stock quotes and charts for Halozyme Therapeutics Inc. (HALO), showing its current price of $121.81...

    Timothy Sykes•10/14/26•Somewhat-Bullish

    HALO Stock Climbs As Patent Win Fuels Bullish Targets

    Halozyme Therapeutics Inc. (HALO) stock climbed 7.67% after a Dutch patent court ruled that Merck’s Keytruda SC infringes Halozyme’s MDASE patent, leading to a broad injunction in Europe. This legal victory...

    StocksToTrade•10/14/26•Bullish

    HALO Stock Climbs As Patent Win And Deals Lift Outlook

    Halozyme Therapeutics Inc. (HALO) stock climbed 6.57% after a Dutch court blocked Merck's Keytruda SC/QLEX due to patent infringement...

    StocksToTrade•10/14/26•Bullish

    HALO Valuation and Fair Value

    P/E
    24.9x
    Forward P/E
    11.4x
    EV/EBITDA
    22.2x
    P/FCF
    17.7x
    PEG
    -2.5x
    P/B
    99.3x
    See GNG's fair value

    HALO Profitability: Margins, ROIC and FCF

    Gross margin
    82.4%
    Operating margin
    59.8%
    Net margin
    24.9%
    ROIC
    18.9%
    ROE
    173.7%
    FCF margin
    48.5%
    FCF yield
    5.7%

    HALO Competitors

    CompanyTicker
    Jazz Pharmaceuticals PLCJAZZ
    ICON PLCICLR
    Neurocrine Biosciences IncNBIX
    Summit Therapeutics PLCSMMT
    Charles River LaboratoriesCRL
    Baxter International IncBAX
    Ascendis Pharma ASASND
    BridgeBio Pharma IncBBIO

    Sector: Healthcare

    HALO Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    2
    Buy
    5
    Hold
    2
    Sell
    0
    Strong Sell
    0

    HALO Bull Case vs Bear Case

    Bull case

    • HALO earns an 18.9% return on invested capital.
    • HALO converts 48.5% of revenue into free cash flow.
    • HALO has a 24.9% net profit margin.

    Bear case

    • HALO has a debt-to-equity ratio of 15.0x.

    HALO Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    -4.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $2.32
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 1 down

    Frequently Asked Questions About HALO

    Does HALO pay dividends?

    Halozyme Therapeutics Inc (HALO) does not currently pay a regular dividend.

    What is HALO's P/E ratio?

    Halozyme Therapeutics Inc has a price-to-earnings (P/E) ratio of 24.94.

    What is HALO's market cap?

    Halozyme Therapeutics Inc (HALO) has a market capitalization of $13.26B with a current stock price of $121.51.

    Related stocks

    Sector: Healthcare

    All stocks starting with H

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In